相似文献
1
Immune system versus tumor: shifting the balance in favor of DCs and effective immunity.
J Clin Invest. 2004 Mar;113(5):664-7. doi: 10.1172/JCI21148.
2
Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
Oncotarget. 2015 Oct 20;6(32):33781-90. doi: 10.18632/oncotarget.5281.
3
Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Clin Cancer Res. 2005 Aug 1;11(15):5566-71. doi: 10.1158/1078-0432.CCR-05-0699.
4
5
Reengineering dendritic cell-based anti-cancer vaccines.
Immunol Rev. 2008 Apr;222:256-76. doi: 10.1111/j.1600-065X.2008.00617.x.
6
Dendritic cell immunotherapy.
Ann N Y Acad Sci. 2013 May;1284:31-45. doi: 10.1111/nyas.12125.
7
Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
J Gene Med. 2003 Aug;5(8):668-80. doi: 10.1002/jgm.387.
8
Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer.
Int J Cancer. 2006 May 1;118(9):2220-31. doi: 10.1002/ijc.21616.
9
Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
J Gene Med. 2004 Aug;6(8):857-68. doi: 10.1002/jgm.576.
10
Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.
Int J Cancer. 2013 Feb 15;132(4):967-77. doi: 10.1002/ijc.27710. Epub 2012 Jul 20.
引用本文的文献
1
Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives.
Front Immunol. 2024 Mar 15;15:1378944. doi: 10.3389/fimmu.2024.1378944. eCollection 2024.
2
Polysaccharide Isolated From Activates TLR4 in Macrophage Cell Lines and Enhances Immune Responses in OVA-Immunized and LLC-Bearing Mouse Models.
Front Pharmacol. 2021 Mar 24;12:609059. doi: 10.3389/fphar.2021.609059. eCollection 2021.
3
Differential gene expression of tumor-infiltrating CD33 myeloid cells in advanced- versus early-stage colorectal cancer.
Cancer Immunol Immunother. 2021 Mar;70(3):803-815. doi: 10.1007/s00262-020-02727-0. Epub 2020 Sep 30.
4
Antitumor immunity of low-dose cyclophosphamide: changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis.
Gastroenterol Rep (Oxf). 2019 Dec 5;8(1):56-65. doi: 10.1093/gastro/goz060. eCollection 2020 Feb.
5
polysaccharide induces toll-like receptor 4 dependent spleen dendritic cell maturation and anti-cancer immunity.
Oncoimmunology. 2017 May 12;6(7):e1325981. doi: 10.1080/2162402X.2017.1325981. eCollection 2017.
6
Engineering cancer microenvironments for 3-D tumor models.
Mater Today (Kidlington). 2015 Dec;18(10):539-553. doi: 10.1016/j.mattod.2015.05.002.
7
Laminarin promotes anti-cancer immunity by the maturation of dendritic cells.
Oncotarget. 2017 Jun 13;8(24):38554-38567. doi: 10.18632/oncotarget.16170.
8
CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer.
Anticancer Agents Med Chem. 2014 Feb;14(2):204-10. doi: 10.2174/18715206113136660375.
9
Current concepts in clinical radiation oncology.
Radiat Environ Biophys. 2014 Mar;53(1):1-29. doi: 10.1007/s00411-013-0497-2. Epub 2013 Oct 20.
10
Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy.
J Neurooncol. 2013 Jan;111(2):103-11. doi: 10.1007/s11060-012-0998-x. Epub 2012 Nov 21.
本文引用的文献
1
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
J Clin Invest. 2004 Mar;113(5):774-83. doi: 10.1172/JCI19762.
2
Cancer vaccines: between the idea and the reality.
Nat Rev Immunol. 2003 Aug;3(8):630-41. doi: 10.1038/nri1150.
3
Tumors as elusive targets of T-cell-based active immunotherapy.
Trends Immunol. 2003 Jun;24(6):335-42. doi: 10.1016/s1471-4906(03)00116-9.
4
The control of immunity and tolerance by dendritic cell.
Pathol Biol (Paris). 2003 Mar;51(2):59-60. doi: 10.1016/s0369-8114(03)00096-8.
5
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
Oncogene. 2003 May 19;22(20):3180-7. doi: 10.1038/sj.onc.1206462.
6
Does the immune system see tumors as foreign or self?
Annu Rev Immunol. 2003;21:807-39. doi: 10.1146/annurev.immunol.21.120601.141135. Epub 2001 Dec 19.
7
A controlled trial of a human papillomavirus type 16 vaccine.
N Engl J Med. 2002 Nov 21;347(21):1645-51. doi: 10.1056/NEJMoa020586.
8
9
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
J Exp Med. 2002 Sep 2;196(5):619-28. doi: 10.1084/jem.20012142.
10
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
J Immunol. 2002 Sep 1;169(5):2756-61. doi: 10.4049/jimmunol.169.5.2756.
Zotero 插件